A comprehensive prognostic stratification for patients with metastatic renal clear cell carcinoma

Yonsei Medical Journal

Volumn 49, Issue 3, 2008, Pages 451-458

  Cho, Kang Su ^a   Choi, Young Deuk ^a   Kim, Se Joong ^b   Kim, Chun Il ^c   Chung, Byung Ha ^a   Seong, Do Hwan ^d   Lee, Dong Hyeon ^e   Cho, Jin Seon ^f   Cho, In Rae ^g   Hong, Sung Joon ^a  

^a Yonsei University   (South Korea)

^b Ajou University   (South Korea)

^c Keimyung University   (South Korea)

^d Inha University   (South Korea)

^e Ewha Womans University   (South Korea)

^f Hallym University   (South Korea)

^g Inje University   (South Korea)

Author keywords

Carcinoma; Immunotherapy; Neoplasm metastasis; Nephrectomy; Prognosis; Renal cell

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ALPHA INTERFERON; ASPARTATE AMINOTRANSFERASE; CALCIUM; FLUOROURACIL; INTERLEUKIN 2; LIVER ENZYME;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BONE METASTASIS; BRAIN METASTASIS; CALCIUM BLOOD LEVEL; CANCER IMMUNOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLEAR CELL CARCINOMA; CLINICAL FEATURE; DISEASE MODEL; ENZYME BLOOD LEVEL; FEMALE; HEMATOCRIT; HUMAN; KIDNEY CARCINOMA; LIVER METASTASIS; LUNG METASTASIS; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NEPHRECTOMY; PROGNOSIS; SURVIVAL TIME; THROMBOCYTE COUNT; THROMBOCYTOSIS; TISSUE DIFFERENTIATION; TUMOR NECROSIS;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, RENAL CELL; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOTHERAPY; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM METASTASIS; NEOPLASM STAGING; NEPHRECTOMY; PROGNOSIS; RETROSPECTIVE STUDIES;

EID: 48649083951     PISSN: 05135796     EISSN: None     Source Type: Journal    
DOI: 10.3349/ymj.2008.49.3.451     Document Type: Article

References (22)

1. Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. N Engl J Med 1996;335:865-75.
2. Pantuck AJ, Zisman A, Belldegrun AS. The changing natural history of renal cell carcinoma. J Urol 2001;166: 1611-23.
3. Flanigan RC, Salmon SE, Blumenstein BA, Bearman SI, Roy V, McGrath PC, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 2001;345:1655-9.
4. Mickisch GH, Garin A, van Poppel H, de Prijck L, Sylvester R; European Organisation for Research and Treatment of Cancer (EORTC) Genitourinary Group. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 2001;358:966-70.
5. Bellmunt J, Montagut C, Albiol S, Carles J, Maroto P, Orsola A. Present strategies in the treatment of metastatic renal cell carcinoma: an update on molecular targeting agents. BJU Int 2007;99:274-80.
6. Atzpodien J, Royston P, Wandert T, Reitz M; DGCIN-German Cooperative Renal Carcinoma Chemo-Immunotherap Trial Group.. Metastatic renal carcinoma comprehensive prognostic system. Br J Cancer 2003;88: 348-53.
7. Leibovich BC, Cheville JC, Lohse CM, Zincke H, Frank I, Kwon ED, et al. A scoring algorithm to predict survival for patients with metastatic clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. J Urol 2005;174:1759-63; discussion 1763.
8. Leibovich BC, Han KR, Bui MH, Pantuck AJ, Dorey FJ, Figlin RA, et al. Scoring algorithm to predict survival after nephrectomy and immunotherapy in patients with metastatic renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer 2003;98:2566-75.
9. Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002;20:289-96.
10. Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999;17:2530-40.
11. Zisman A, Pantuck AJ, Dorey F, Said JW, Shvarts O, Quintana D, et al. Improved prognostication of renal cell carcinoma using an integrated staging system. J Clin Oncol 2001;19:1649-57.
12. Zisman A, Pantuck AJ, Wieder J, Chao DH, Dorey F, Said JW, et al. Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. J Clin Oncol 2002;20:4559-66.
13. Frank I, Blute ML, Cheville JC, Lohse CM, Weaver AL, Zincke H. An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score. J Urol 2002;168:2395-400.
14. de Forges A, Rey A, Klink M, Ghosn M, Kramar A, Droz JP. Prognostic factors of adult metastatic renal carcinoma: a multivariate analysis. Semin Surg Oncol 1988;4:149-54.
15. Lopez Hänninen E, Kirchner H, Atzpodien J. Interleukin-2 based home therapy of metastatic renal cell carcinoma: risks and benefits in 215 consecutive single institution. patients. J Urol 1996;155:19-25.
16. Jones M, Philip T, Palmer P, von der Maase H, Vinke J, Elson P, et al. The impact of interleukin-2 on survival in renal cancer: a multivariate analysis. Cancer Biother 1993;8:275-88.
17. Palmer PA, Vinke J, Philip T, Negrier S, Atzpodien J, Kirchner H, et al. Prognostic factors for survival in patients with advanced renal cell carcinoma treated with recombinant interleukin-2. Ann Oncol 1992;3:475-80.
18. Elson PJ, Witte RS, Trump DL. Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma. Cancer Res 1988;48:7310-3.
19. Fosså SD, Kramar A, Droz JP. Prognostic factors and survival in patients with metastatic renal cell carcinoma treated with chemotherapy or interferon-alpha. Eur J Cancer 1994;30A:1310-4.
20. Amin MB, Amin MB, Tamboli P, Javidan J, Stricker H, de-Peralta Venturina M, et al. Prognostic impact of histologic subtyping of adult renal epithelial neoplasms: an experience of 405 cases. Am J Surg Pathol 2002;26: 281-91.
21. Berndt SI, Carter HB, Schoenberg MP, Newschaffer CJ. Disparities in treatment and outcome for renal cell cancer among older black and white patients. J Clin Oncol 2007;25:3589-95.
22. Tripathi RT, Heilbrun LK, Jain V, Vaishampayan UN. Racial disparity in outcomes of a clinical trial population with metastatic renal cell carcinoma. Urology 2006;68: 296-301.